London
· Delayed Price · Currency is GBP · Price in EUR Hyloris Pharmaceuticals Statistics
Total Valuation
LON:0AB6 has a market cap or net worth of GBP 151.71 million. The enterprise value is 132.64 million.
| Market Cap | 151.71M |
| Enterprise Value | 132.64M |
Important Dates
The next estimated earnings date is Wednesday, April 30, 2025.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 12.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.27 |
| PB Ratio | 5.71 |
| P/TBV Ratio | 6.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -25.29 |
| EV / Sales | 15.47 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -23.83 |
Financial Position
The company has a current ratio of 4.15, with a Debt / Equity ratio of 0.06.
| Current Ratio | 4.15 |
| Quick Ratio | 4.12 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.27 |
| Interest Coverage | -16.08 |
Financial Efficiency
Return on equity (ROE) is -17.81% and return on invested capital (ROIC) is -10.16%.
| Return on Equity (ROE) | -17.81% |
| Return on Assets (ROA) | -8.53% |
| Return on Invested Capital (ROIC) | -10.16% |
| Return on Capital Employed (ROCE) | -17.78% |
| Revenue Per Employee | 169,478 |
| Profits Per Employee | -107,034 |
| Employee Count | 49 |
| Asset Turnover | 0.23 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.00% in the last 52 weeks. The beta is 0.32, so LON:0AB6's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | -45.00% |
| 50-Day Moving Average | 5.83 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 55.54 |
| Average Volume (20 Days) | 695 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, LON:0AB6 had revenue of GBP 8.30 million and -5.24 million in losses.
| Revenue | 8.30M |
| Gross Profit | 8.12M |
| Operating Income | -5.03M |
| Pretax Income | -5.24M |
| Net Income | -5.24M |
| EBITDA | -4.01M |
| EBIT | -5.03M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 19.97 million in cash and 1.50 million in debt, giving a net cash position of 18.47 million.
| Cash & Cash Equivalents | 19.97M |
| Total Debt | 1.50M |
| Net Cash | 18.47M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 26.58M |
| Book Value Per Share | n/a |
| Working Capital | 18.64M |
Cash Flow
In the last 12 months, operating cash flow was -5.54 million and capital expenditures -23,982, giving a free cash flow of -5.57 million.
| Operating Cash Flow | -5.54M |
| Capital Expenditures | -23,982 |
| Free Cash Flow | -5.57M |
| FCF Per Share | n/a |
Margins
Gross margin is 97.74%, with operating and profit margins of -60.52% and -63.15%.
| Gross Margin | 97.74% |
| Operating Margin | -60.52% |
| Pretax Margin | -63.15% |
| Profit Margin | -63.15% |
| EBITDA Margin | -48.28% |
| EBIT Margin | -60.52% |
| FCF Margin | n/a |
Dividends & Yields
LON:0AB6 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -3.46% |
| FCF Yield | -3.67% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0AB6 has an Altman Z-Score of 14.7.
| Altman Z-Score | 14.7 |
| Piotroski F-Score | n/a |